Blnd Ismail

Mr. Blnd Ismail

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
HAHemn Abdulrahman Abdullah
Hemn Abdulrahman Abdullah
DSDarya Nadir Saeed
Darya Nadir Saeed
SISherzad Ali Ismael
Sherzad Ali Ismael
MBMarwan Abdullah Barzani
Marwan Abdullah Barzani
BIBlnd Ismail
Blnd Ismail
AFAbdullah Haider Flayeh
Abdullah Haider Flayeh
Background: Minimally invasive coronary artery bypass techniques are increasingly adopted to reduce surgical trauma and enhance recovery. This study aimed to compare early clinical outcomes of endoscopic-assisted minimally invasive direct coronary artery bypass (EA-MIDCAB)—predominantly via a periareolar incision—with conventional full sternotomy coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease. Methods: We retrospectively analyzed 393 patients diagnosed with multivessel coronary artery disease who underwent coronary artery bypass grafting (CABG) between February 2021 and May 2025. Of these, 332 underwent endoscopic-assisted minimally invasive direct CABG (EA-MIDCAB), and 61 underwent conventional full sternotomy CABG. Baseline characteristics, intraoperative and postoperative outcomes, and complication rates were compared between groups. Statistical analyses were performed using appropriate tests, with significance defined as p < 0.05. Results: Baseline characteristics and coronary stenosis distribution were comparable between groups. EA-MIDCAB patients demonstrated significantly lower cardiopulmonary bypass (CPB) usage (11.1% vs. 83.6%, p < 0.001), reduced red blood cell transfusion requirements (0.82 vs. 1.56 pints, p < 0.001), and fewer graft conduits (≥ 4 conduits: 0.6% vs. 19.2%, p < 0.001). Despite a higher prevalence of diabetes and hypertension, short-term outcomes—including mortality, renal dysfunction, and postoperative myocardial infarction—were similar between the two groups. Conclusions: EA-MIDCAB offers a safe and effective alternative to full sternotomy CABG for multivessel coronary artery disease, with reduced surgical trauma and transfusion needs.

12 May 2026 in Immuno
Verified
Journal Article
Open access
PDF file
SSshukur smail
shukur smail
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
BIBlnd Ismail
Blnd Ismail
AAAkhter Ahmed Ahmed
Akhter Ahmed Ahmed
ABAhmed Abdulrazzaq Bapir
Ahmed Abdulrazzaq Bapir
Christer JansonChrister Janson
Christer Janson
Living therapies, including chimeric antigen receptor T (CAR-T) cells, oncolytic viruses (OVs), and bacteria-based platforms, are emerging as promising approaches in cancer treatment because they can directly target tumors and modulate anti-tumor immunity. This narrative review summarizes current knowledge on these therapies, focusing on their mechanisms of action, therapeutic applications, major limitations, and recent advances in genetic engineering, synthetic biology, and delivery systems. CAR-T cell therapy has shown substantial clinical success in hematological malignancies through the genetic redirection of T cells against tumor-associated antigens, although its efficacy in solid tumors remains limited by antigen heterogeneity and the immunosuppressive tumor microenvironment (TME). OVs selectively infect and lyse malignant cells while also stimulating local and systemic immune responses, and engineered OVs may further enhance therapeutic activity by reshaping the TME. Bacteria-based therapies exploit the natural tumor-targeting ability of selected strains, particularly in hypoxic regions, to deliver therapeutic agents and activate immune responses. Despite encouraging progress, safety concerns, immune-related barriers, and tumor complexity remain major challenges. Overall, integrating living therapies with modern biotechnological advances and existing treatment modalities may support more personalized and synergistic strategies for cancer management.

7 September 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
BIBlnd Ismail
Blnd Ismail
AAAreen Muhsin Abdulrahman
Areen Muhsin Abdulrahman
SSshukur smail
shukur smail
Acinetobacter baumannii is a major multidrug-resistant nosocomial pathogen, yet its population structure and evolutionary dynamics in the Middle East remain poorly understood. This study compared Middle Eastern and global isolates to identify regional genomic signatures. We analyzed 199 high-quality A. baumannii genomes (100 Middle Eastern and 99 global) using pangenome reconstruction, core-genome phylogenetics, resistome and virulome profiling, genome-wide association studies, and machine learning. The pangenome comprised 10,971 genes, including 1102 unique to Middle Eastern isolates. Compared with global isolates, Middle Eastern genomes carried fewer antimicrobial resistance genes but a higher abundance of mobility-associated genes. A distinct regional cluster was dominated by sequence type 2 (ST2), representing 66% of Middle Eastern isolates. Genome-wide association analysis identified region-associated markers, particularly ISAba1 variants and the tufB gene. A Random Forest classifier distinguished Middle Eastern from global isolates with 79.9% accuracy. Virulence gene repertoires were similar between groups, and resistance gene burdens remained stable over time. Middle Eastern A. baumannii isolates exhibit a distinct regional genomic signature characterized by accessory-genome conservation, reduced genomic heterogeneity, enrichment of ISAba1-associated markers, and increased mobility-associated gene content. These features differentiate the regional population from globally distributed isolates despite the similar prevalence of the ST2/IC2 lineage in both cohorts.

17 September 2026 in BioMedInformatics
Verified
Journal Article
Open access
PDF file
SOSaman I. Othman
Saman I. Othman
RSRebaz Hamza Salih
Rebaz Hamza Salih
KAKamal Al-Barznji
Kamal Al-Barznji
KAKarzan M. Abdullah
Karzan M. Abdullah
MAMuhamed Aydin Abbas
Muhamed Aydin Abbas
SSshukur smail
shukur smail
Rapid selection of appropriate antimicrobial therapy is important for improving patient outcomes and supporting antimicrobial stewardship, particularly in the context of increasing antimicrobial resistance (AMR). Conventional antimicrobial susceptibility testing (AST), although essential for clinical decision-making, may not provide actionable susceptibility information immediately. This study develops an explainable multi-label machine learning framework for patient-specific antibiotic recommendation based on susceptibility prediction and ranked decision support using routinely collected clinical microbiology data. The framework integrates leakage-controlled preprocessing, microbiological and demographic feature representation, multi-label susceptibility encoding, One-vs-Rest ensemble learning, probability-based antibiotic ranking, statistical evaluation, temporal validation, and SHapley Additive exPlanations (SHAP). The dataset comprised 234 clinical records, of which 196 bacterial/other records were retained for the primary analysis after excluding 38 fungal records. A chronological partition produced 156 development records and 40 temporally held-out test records. Thirty-three antibiotic susceptibility labels were retained based on development-set availability. XGBoost, Random Forest, and LightGBM were evaluated using five-fold out-of-fold (OOF) validation. Random Forest was selected for the final recommendation and explainability analyses based on its overall performance, achieving a Micro-F1 of 0.4204, Macro-F1 of 0.3003, AUROC of 0.7069, AUPRC of 0.3979, and Precision@5 of 0.3962. A leakage-safe local antibiogram was additionally evaluated as a population-level ranking baseline, achieving a Precision@5 of 0.3077. Feature ablation showed that the combination of organism and age produced the highest OOF Micro-F1 (0.4635) and AUROC (0.7186), while the addition of gender and specimen type improved selected ranking measures but did not consistently improve aggregate classification performance. On the temporally held-out test cohort, Random Forest achieved a Micro-F1 of 0.4267, AUROC of 0.7447, AUPRC of 0.4892, and Precision@5 of 0.4350. SHAP analysis was completed for all 33 antibiotic-specific classifiers, providing global and antibiotic-level explanations of model behavior. The framework provides an interpretable approach for ranking potentially susceptible antibiotics at the patient level and is intended as clinical decision support rather than an autonomous prescribing system. Further external and prospective multicentre validation, including dedicated evaluation of challenging cases such as pan-drug resistance, is required before clinical deployment.

3 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSshukur smail
shukur smail
RSRebaz Hamza Salih
Rebaz Hamza Salih
BIBlnd Ismail
Blnd Ismail
IMIvan Sdiq Maghdid
Ivan Sdiq Maghdid
RYRaya Kh. Yashooa
Raya Kh. Yashooa
Christer JansonChrister Janson
Christer Janson
Asthma is a heterogeneous chronic airway disease in which oxidative stress (OS) plays a central mechanistic role beyond classical immune-mediated inflammation. Reactive oxygen and nitrogen species (ROS/RNS), generated by recruited inflammatory cells and activated airway structural cells, drive epithelial injury, mucus hypersecretion, airway remodeling, and modulate key transcription factors including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. This review synthesizes current evidence on the multilevel redox-based determinants of asthma severity, spanning from genetic polymorphisms to circulating biomarkers. We examine serum antioxidant enzymes, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), peroxiredoxins (PRDXs), and the thioredoxin (Trx) system as dynamic indicators of systemic redox status and disease severity, alongside oxidative enzymes including NADPH oxidases and dual oxidases (NOX/DUOX), xanthine oxidase (XO), and myeloperoxidase (MPO) that serve as upstream sources of airway oxidant burden. Functional genetic polymorphisms in antioxidant genes (SOD2, CAT, glutathione S-transferase mu 1/glutathione S-transferase theta 1 (GSTM1/GSTT1), heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (Nrf2/KEAP1)) and oxidative enzyme genes including nitric oxide synthase 1/2/3 (NOS1/2/3), MPO, cytochrome b-245 alpha chain (CYBA), and xanthine dehydrogenase (XDH) are reviewed as modulators of individual redox capacity and asthma susceptibility, with particular attention to gene–environment interactions. We further discuss oxidative damage biomarkers, including malondialdehyde (MDA), 8-isoprostanes, 4-hydroxynonenal, 8-oxo-7, 8-dihydro-2′-deoxyguanosine, protein carbonyls, 3-nitrotyrosine, and advanced oxidation protein products as indicators of lipid, DNA, and protein oxidation that correlate with disease activity and control. The roles of micronutrient cofactors in modulating antioxidant enzyme function and their potential as contextual biomarkers are also addressed. Additionally, emerging evidence on microRNAs (miRNAs) linked to OS biology in asthma is presented. Finally, we critically evaluate the challenges limiting clinical translation, including biomarker non-specificity, analytical variability, gene–environment complexity, and the absence of standardized reference ranges. This integrated framework supports the development of multilevel redox prognostic panels combining genetic, enzymatic, and oxidative damage readouts for improved asthma phenotyping, severity stratification, and personalized therapeutic approaches.